Expression of GPR30, ERα and PR in thyroid carcinoma tissues and their association with thyroid carcinoma

李飞; 罗浩军; 罗平; 杨光伦; 涂刚

您当前的位置：

首页 >

文章列表页 >

Expression of GPR30, ERα and PR in thyroid carcinoma tissues and their association with thyroid carcinoma

更新时间：2026-01-09

- Expression of GPR30, ERα and PR in thyroid carcinoma tissues and their association with thyroid carcinoma
- Journal of Army Medical University Vol. 33, Issue 16, Pages: 1691-1694(2011)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R736.1;R392.3;R730.23
- Published：2011
- 稿件说明：
移动端阅览
李飞,罗浩军,罗平,杨光伦,涂刚.雌激素受体GPR30、ERα和PR在甲状腺癌组织中的表达及相关性[J].陆军军医大学学报(原第三军医大学学报),2011,33(16):1691-1694.

　Li Fei,Luo Haojun,Luo Ping,Yang Guanglun,Tu Gang.Expression of GPR30, ERα and PR in thyroid carcinoma tissues and their association with thyroid carcinoma[J].J Amry Med Univ (J Third Mil Med Univ),2011,33(16):1691-1694.
李飞,罗浩军,罗平,杨光伦,涂刚.雌激素受体GPR30、ERα和PR在甲状腺癌组织中的表达及相关性[J].陆军军医大学学报(原第三军医大学学报),2011,33(16):1691-1694. DOI：

　Li Fei,Luo Haojun,Luo Ping,Yang Guanglun,Tu Gang.Expression of GPR30, ERα and PR in thyroid carcinoma tissues and their association with thyroid carcinoma[J].J Amry Med Univ (J Third Mil Med Univ),2011,33(16):1691-1694. DOI：

摘要

目的探讨雌激素受体GPR30、ERα和PR在甲状腺癌组织中的表达及其相关性。方法选取重庆医科大学附属第一医院病理科2006-2009年101例甲状腺癌组织标本，包括乳头状腺癌83例、滤泡状腺癌9例、髓样癌6例、未分化腺癌3例，患者年龄45.9（9～93）岁；采用免疫组化S-P法检测甲状腺癌组织中GPR30、ERα和PR的表达，分析其与肿瘤临床病理特征之间，以及相互间的差异。结果甲状腺癌组织中GPR30、ERα和PR主要表达于细胞质，少量表达于细胞核，阳性表达率分别为78.2%、85.1%、79.2%；除在≥45岁年龄组患者肿瘤中ERα表达率高于45年龄组外（r=-0.2383，P0.05），GPR30和ERα的表达与患者年龄、性别、肿瘤大小、淋巴结转移、病理类型、TNM分期等临床病理因子及患者MACIS预后评分无统计学差异（P0.05）；GPR30与ERα(r=0.2518)、PR(r=0.3207)的表达呈正相关。结论雌激素受体GPR30和ERα共同参与甲状腺癌的发生、发展，可能是潜在的治疗靶点。

Abstract

Objective To evaluate the expression of G-protein coupled receptor 30 (GPR30)

estrogen receptor α (ERα) and progesterone receptor (PR) in thyroid carcinoma (TC) tissues

and to study their association with thyroid carcinoma. Methods Immunohistochemistry (S-P) assay was used to detect the expression of GPR30

ERα and PR in the paraffin-embedded TC tissue specimens from 101 patients (age at 45.9

9-93 years). The specimens were collected in our hospital from 2006 to 2009 and included 83 cases of papillary adenocarcinoma

9 cases of follicular adenocarcinoma

6 cases of medullary carcinoma and 3 cases of undifferentiated carcinoma. The association of GPR30

ERα and PR expression with TC clinicopathologic features and the correlation among them were analyzed. Results GPR30

ERα and PR were expressed mainly in cytoplasm and rarely in cell nuclei

with positive expression rates of 78.2%

85.1% and 79.2%

respectively. Their expression displayed no significant association with clinicopathological determinants (age

sex

tumor size

lymph node metastasis

pathologic subtype and TNM stage) and MACIS prognostic score (P0.05)

except that ERα had a higher positive expression rate in patients aged 45 years and older than in patients aged less than 45 years old (r=-0.2383

P0.05). GPR30 expression was positively correlated with ERα expression (r=0.2518) and PR expression (r=0.3207). Conclusion As estrogen receptors

GPR30 and ERα both contribute to the development of TC and

therefore

may be potential therapy targets.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

A novel estrogen receptor expression stratification (low/moderate/high) based on Chinese population provides more accurate prognosis prediction for HR⁺/HER2^- early breast cancer patients

Differences in the expression of 4 progesterone receptor antibodies EP2, SP2, 1E2, and 16 in nonspecific invasive breast cancers

Expression of P504s and claudin-4 in prostate cancer and prognostic value of their combined detection

17β-estradiol promotes proliferation, migration and TFF1 secretion in papillary thyroid cancer K-1 cells

Expression and clinical significance of pyruvate dehydrogenase kinase 4 in colon cancer

Related Author

WANG Chengfang

ZHOU Yuqin

ZHANG Yanling

QI Xiaowei

ZHANG Yi

黎三艳

郑眉嵩

陈余鹏

Related Institution

Department of Breast and Thyroid Surgery， First Affiliated Hospital， Army Medical University （Third Military Medical University）

⁰